May 2, 2016
Oncternal Therapeutics, a new cancer-focused biotechnology startup, has signed a wide-ranging licensing agreement with UC San Diego to develop and commercialize antibodies and antibody-related binding agents.
January 31, 2023
UC San Diego scientists developed an artificial intelligence tool that could accelerate the development of new high affinity antibody drugs.
January 27, 2022
…How Protective are COVID Antibodies? Campus volunteers needed for largest study to date to understand Covid-19 immunity. The University of California San Diego is conducting what is believed to be the largest research study yet of SARS-CoV-2 antibodies and the protection they impart against contracting COVID-19. The ZAP COVID-19 (NeutraliZing…
October 19, 2016
Experts at the recent Global Biological Standards Institute workshop — as well as Cell Press and Thermo Fisher Scientific — have agreed to adopt reproducibility standards first proposed by QI affiliate Anita Bandrowski and her colleagues.
November 5, 2020
…of Cost for COVID-19 Antibody Testing Testing for COVID-19 antibodies can provide important information for communities battling an outbreak. These tests can inform epidemiologists whether someone has had an infection, even if they were asymptomatic. Yet for testing to provide a good understanding, take-up needs to be broad and independent…
March 25, 2013
Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells.
February 18, 2021
UC San Diego researchers report that individual immune response to SARS-CoV-2 may be limited by a set of variable genes that code for cell surface proteins essential for the adaptive immune system. The finding may help explain why COVID-19 immunity varies by individual.
April 17, 2020
Physicians and scientists at UC San Diego Health have launched a pair of serological tests that will look for novel coronavirus antibodies—evidence in persons tested that they have previously been infected by the viral cause of COVID-19, even if they never experienced tell-tale symptoms.
August 5, 2020
The National Institutes of Health will soon launch a Phase II clinical trial to evaluate the safety and efficacy of potential new therapeutics for COVID-19, including the use of investigational synthetic monoclonal antibodies. Davey Smith of UC San Diego is the protocol chair and answers questions.
April 7, 2014
The difference between an immune response that kills cancer cells and one that conversely stimulates tumor growth can be as narrow as a “double-edged sword,” report researchers at the University of California, San Diego School of Medicine in the April 7, 2014 online issue of the Proceedings of the National…
